The efficacy and safety of alpha-1 adrenoceptor blocker (Alfuzosin) in improving symptoms and pain in patients with DJ ureteric stent
DOI:
https://doi.org/10.61841/3z7sx765Keywords:
alpha-1, adrenoceptor, blocker, Alfuzosin, DJ ureteric stentAbstract
Objective: We conducted a randomized study to evaluate the effect of (Alfuzosin) in improving urinary symptoms and pain in patients with indwelling double-pigtail ureteral stent using specific questionnaire.
Patient and Method: We prospectively enrolled 60 patients (30 men and 30 women mean age 34.6 years) who underwent ureteral stent positioning and were assigned into one of two study groups. In group A(n=30) patients were discharged with a prescription for (Alfuzosin) 10 mg once daily. In group B(n=30), patients received no α1 blocker (control group).
Results: One week after stent placement (visit week 1[W1]), analyses of ureteral stent symptoms questionnaire showed a significant worsening of urinary symptoms (14.2 v 27.2 P=0.008) and pain (5.3 v 20.4 P=0.002) in patients not receiving (Alfuzosin). There was also a significant difference in the mean visual analogue score (VAS) of health scale between the two groups (P<0.001) compared with the results obtained at the(visit week 4 [W4]) evaluation. The proportion of patients developing acute attacks of pain and the numbers of diclofenac injections at week 1 varied between the two groups in a highly statistically significant manner (P<0.0001).
Conclusions: Our findings indicate that administration of (Alfuzosin) has a significant effect on stent-related urinary symptoms and pain for improving quality of life. Further clinical research in this field is needed to better define the role of α1-blockers in current clinical practice.
Downloads
References
1. Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967;97:840-4.
2. Monga M. Ureteral Stents: New materials and designs. In: Williams JC, Evans A, Lingeman J, editors. Renal Stone Disease. 2nd ed. Melville NY, American Institute of Physics; 2008. p. 173-81.
3. Chew BH, Knudsen BH and Denstedt D. The use of stents incontemporary urology. Curr Opin Urol 2004;14:111-5.
4. Jeong H, Hwak C, Lee SE. Ureteric stenting after ureteros- copy for ureteric stones: a prospective randomized study asse-ssing symptoms and complications. BJU Int 2004; 93:1032-5.
5. Knudsen BE, Beiko DT, Denstedt JD. Stenting after uretero-scopy: pros and cons. Urol Clin N Am 2004;31:173-80.
6. Joshi HB, Okeke A, Newns N, et al .Characterization of urinary symptoms in patients with ureteral stents. Urology 2002;59:511-9.
7. Hao P, Li W, Song C, et al . Clinical Evaluation Of Double-Pigtail in Patients with Upper Urinary Tract Diseases: Report of 2685 cases. J Endourol 2008;22:65-70.
8. Thomas R. Indwelling ureteral stents: Impact of material and shape on patient comfort. J Endourol 1993;7:137-40.
9. Sur RL, Haleblian GE, Cantor D, et al .Efficacy of intra- vesical ropivacaine injection on urinary symptoms following ureteral stenting: a randomized, controlled study. J Endourol 2008;22:473-8.
10. Chew BH, Knudsen BE, Nott L, et al . Pilot Study of Ureteral Movement in Stented Patients: First Step in Understanding Dynamic Ureteral Anatomy to Improve Stent Discomfort. J Endourol 2007;21:1069-75.
11. Al-Kandari AM, Al-Shaiji TF, Shaaban H, et al . Effects of Proximal and Distal Ends of Double-J Ureteral Stent Position on Postprocedural Symptoms and Quality of Life: a Randomized Clinical Trial. J Endourol 2007;21:698-702.
12. Ramsay JW, Payne SR, Gosling PT, et al . Effects of double-J stenting on unobstructed ureter: an experimental and clinical study. Br J Urol 1985;57:630-4.
13. Ho CH, Chen SC, Chung SD, et al. Determining the Apropriate Length of a Double-Pigtail Ureteral Stent by Both Stent Configurations and Related Symptoms. J Endourol 2008;22:1427-31.
14. Saltzman B. Ureteral stents: indications, variations and complications. Urol Clin N Am 1988;15:481-91.
15. Breau RH, Norman RW. Optimal prevention and management of proximal ureteral migration and remigration. J Urol2001;166:890-3.
16. Joshi HB, Stainthorpe A, Keeley FX, et al. Indwelling Ureteral Stents: Evaluation of Quality of Life to Aid Outcome Analysis. J Endourol 2001;15:151-4.
17. Joshi HB, Newns MN, Stainthorpe A, et al . Ureteral stent symptom questionnaire: development and validation of amultidi mensional quality of life measure. J Urol 2003;169:1060-4.
18. El-Faqih SR , Shamsuddin AB, Chakrabarti A , et al. Polyurethane internal ureteral stents in treatment of stone patients: morbidity related to indwelling times. J Urol 1991;146:1487-91.
19. Cadieux PA, Chew BH, Knudsen BE, et al. Triclosan loaded ureteral stents decrease Proteus mirabilis 296 infection in a rabbit urinary tract infection model. J Urol 2006;175:2331.
20. Liatsikos EN, Hom D, Dinlenc CZ, et al. Tail Stent versus reentry tube: A randomized comparison after percutaneous stone extraction. Urology 2002;59:15-9.
21. Watterson JD, Cadieux PA, Beiko DT, et al. Oxalate-degrading enzymes form Oxalobacter formigenes: A novel device coating to reduce urinary tract biomaterial-related encrustation. J Endourol2003;17:269-74.
22. Riedl CR, Witkowski M, Plas E, Pflueger H. Heparin coating reduces encrustation of ureteral stents: A preliminary report. Int J Antimicrob Agents 2002;19:507-10.
23. Zupkas P, Parsons CL, Percival C, Monga M. Pentosanpoly-sulafte coating of silicone reduces encrustation. J Endourol 2000;14:483-8.
24. Multanen M, Tammela TL, Laurila M, Seppδlδ J, Vδlimaa T, Tφrmδlδ P, et al. Biocompatibility, encrustation andbiodegra-dation of ofloxacine and silver nitrate coated poly-Llactic acid stents in rabbit urethra. Urol Res 2002;30:227-32.
25. Vanderbrink BA, Rastinehead AR, Ost MC, Smith A. Encrusted Urine management . A preliminary report .2004; 18:509-10.
26. Surg JR, Seymor RA, Ong KS. Pain measurement in humans. Department of oral and maxillofascial surgery , Singapore. 2004,15-27.
27. The PDR® Electronic Library. Thomson Medical Economics, NJ: 2003.
28. Auge BK, SarvisJA, L'Esperance JO, Preminger G. Practice Patterns of Ureteral Stenting after Routine Ureteroscopic Stone Surgery: A Survey of Practicing Urologists. J Endourol 2007.
29. Nabi G,Cook J, N,Dow J, McClinton S. Outcomes of stenting after uncomplicated ureteroscopy. Systemic review and metaanalyses. BMJ 2007; 337;572.
30. Damiano R, Autorino R, Esposito C. Stent positioning after ureteroscopy for urinary calculi. Eur Uro. 2004;46:381-388.
31. Richard Beddingfield,Renato N Pedro.Alfuzosin to Releive Uretral Stent Discomfort.THE JORNAL OF UROLOGY Vol.181,170-176, January 2009.
32. Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvement in bladder storage function by alfuzosin depends on suppression of C-fiber urethral afferent activity in rats. J Urol.2007;177:771-775.
33. Pharmaceutical standard: Professed Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH) Adjunctive Therapy in Acute Urinary Retention (AUR) ATC Code: G04CA01. Date of Revision: July 30, 2010. sanofi-aventis Canada Inc. 2150 St.Elzear Blvd. West Laval, Quebec H7L 4A8.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
